Pharmaceutical distribution is moving closer to the centre of healthcare strategy.

As speciality medicines, biologics, GLP-1 therapies and vaccines account for a growing share of market expansion, the ability to move products safely, quickly and with full visibility is becoming a core competitive advantage.

In this article, we look at why wholesale and distribution now sit closer to the centre of global pharma strategy.

The global Pharma Wholesale and Distribution market is estimated at US$1,033.0 billion in 2025, with Visiongain projecting a 7.8% CAGR through 2035.

Visiongain Top Takeaways

• Pharma wholesale and distribution is moving from an operational support function to a strategic growth enabler
• Speciality medicines, biologics, GLP-1 therapies and vaccines are increasing demand for validated cold-chain capacity.
• Automation, digitalisation and track-and-trace systems are becoming essential as distributors manage tighter delivery windows and more complex order profiles
• Hospitals, clinics, pharmacies and online providers are placing greater value on visibility, reliability and speed
• Trade disruption, tariffs and supply-chain pressure are making resilience a core part of distributor value

Speciality medicines are changing the distribution model

Speciality medicines are putting new pressure on pharma wholesale and distribution.

Biologics, GLP-1 therapies, oncology products, vaccines and advanced therapies often need tighter temperature control, more precise handling, faster fulfilment and stronger end-to-end visibility than traditional small-molecule products. That raises the operational bar and changes the commercial value of distribution.

Visiongain’s latest analysis estimates that the market will grow at a 7.8% CAGR between 2025 and 2035, reflecting the growing importance of advanced distribution models across branded medicines, generics, OTC products, vaccines, medical devices and speciality therapies.

For manufacturers, the distribution partner is evolving into part of the product strategy. A high-value therapy cannot succeed commercially if access is unreliable, stock visibility is weak, or the distribution pathway is not trusted by hospitals, clinics and speciality pharmacies.

Recent investment shows how quickly expectations are changing. Cencora has announced plans to invest US$1 billion through 2030 to expand its U.S. pharmaceutical distribution network, including new facilities in Ohio and California, alongside expanded speciality and cold-chain capacity in Alabama. This is not just extra capacity. It is infrastructure designed for higher-value, higher-complexity medicines.

For distributors, the opportunity is clear: those able to support complex product flows can move beyond lower-margin volume distribution and build a stronger position in premium therapy areas.

Visiongain insight: Speciality distribution is now acting as a route-to-market advantage. Manufacturers need partners who can protect product integrity, maintain service levels, and support access into clinical settings. Distributors with these capabilities are better positioned to capture higher-value product flows.

Automation is setting new operating benchmarks

Automation is increasingly being viewed as a practical requirement in pharma distribution.

As product mixes become more complex and delivery windows tighten, wholesalers need systems that improve speed, accuracy and labour productivity without weakening compliance.

Geo-Young’s AutoStore-powered Smart Hub in Incheon shows how quickly expectations are changing. The facility uses 40,000 bins, 80 robots and picking technology capable of processing up to 1,200 items per hour.

Other major players are also investing. EVERSANA’s new 358,000 sq ft Memphis distribution centre includes expanded cold-chain capability, an upgraded warehouse management system and AI-enabled warehouse automation robots, while Cardinal Health’s planned 230,000 sq ft Indianapolis facility will use Swisslog robotic storage and retrieval technology.

For wholesalers, automation is part of the cost, accuracy and service model needed to compete in higher-complexity distribution.

Visiongain insight: Automation is moving from warehouse improvement to strategic infrastructure. Distributors that combine robotics, inventory visibility and cold-chain control will be better placed to support higher-value products while protecting margins.

Customer expectations are shifting from price to service

Hospitals, clinics, pharmacies and online providers are asking more from wholesale partners.

Product availability still matters, but it is no longer the full measure of value. Buyers now look closely at:

• delivery reliability
• digital ordering
• stock visibility
• returns management
• traceability
• responsiveness when demand changes

This applies across OTC, institutional supply, branded pharmaceuticals and speciality therapies. As healthcare systems face rising cost and capacity pressures, distributors are increasingly expected to reduce operational friction, improve visibility and support continuity of supply.

For generic and OTC players, service is shifting toward a more important source of differentiation. For branded and speciality distributors, loyalty is increasingly tied to supply-chain agility, delivery confidence and support for more complex product requirements.

The market is moving away from a narrow focus on cost. Technology, visibility and operational reliability are now central to customer retention.

Visiongain insight: Service quality is becoming a commercial advantage in pharma distribution. Distributors that combine reach with visibility, responsiveness and reliable fulfilment will be better placed to defend margins and strengthen customer relationships.

Resilience is now part of the value proposition

Supply-chain disruption, medicine shortages, trade policy uncertainty and geopolitical risk have made resilience a more important part of pharma distribution.

For wholesalers and distributors, this means more than holding extra stock. It requires diversified sourcing, regional hub strategies, better demand forecasting, closer supplier coordination and clearer visibility across inventory and fulfilment.

U.S. trade tariffs add further pressure. Tariffs applied to APIs, intermediates, excipients, packaging materials, medical devices and finished-dose imports can increase landed costs, squeeze distributor margins and make procurement cycles harder to plan. For multi-party distributors and institutional supply models, this is especially difficult where contract pricing cannot be adjusted quickly.

The trade-off is becoming sharper. Higher inventory buffers can protect service levels, but they also tie up working capital. Longer lead times and customs uncertainty can weaken contract stability, while shifts in sourcing may change warehousing and fulfilment routes.

In this environment, resilience has clear commercial value. Manufacturers and healthcare customers want partners that can keep products moving when market conditions change.

Visiongain insight: Resilience is now a test of distributor quality. Partners that can protect supply continuity, manage cost volatility and maintain service levels under pressure will be better placed to win trust from manufacturers, hospitals and institutional buyers.

Market Outlook

The pharma wholesale and distribution market is entering a more strategic decade.

Growth will be shaped not only by rising medicine demand, but by the changing nature of the products moving through the system. Speciality medicines, biologics, GLP-1 therapies, vaccines and medical devices all require greater control, visibility and service reliability than traditional high-volume pharmaceutical flows.

This creates an opportunity for wholesalers and distributors to invest in automation, cold-chain capacity, digital infrastructure, and service-led fulfilment. It also raises the bar for competition. Players that cannot support higher-complexity products may face greater pressure in lower-margin generic and OTC categories.

By 2035, pharma distribution is likely to be judged less by network size alone and more by capability. The strongest players will be those able to protect product integrity, manage volatility, serve fragmented healthcare channels and support manufacturer access strategies across multiple product categories and regions.

The market is no longer only about moving medicines. It is about building the infrastructure that allows modern pharma to reach patients safely, reliably and at commercial scale.

Visiongain insight: The next phase of growth will favour distributors that combine scale with specialist capability. Cold-chain strength, automation, visibility and service reliability will increasingly determine which partners manufacturers trust with their most valuable products.

From Visiongain

Visiongain’s Pharma Wholesale and Distribution Market Report 2025-2035 examines how speciality medicines, cold-chain demand, automation, tariff pressure, healthcare access, and service-led distribution are reshaping the global wholesale and distribution market.

The report provides detailed revenue forecasts by type, distribution type, product category, end user and key regions, alongside company intelligence on leading players including Cencora, Cardinal Health, McKesson, Sinopharm Group, Medipal Holdings, Geo-Young and Walgreens Boots Alliance.

To identify the segments, regions and companies best positioned for growth, request sample pages

Latest Reports

Detailed market forecasts, competitive analysis, and sector insights help R&D, manufacturing, supply chain, and commercial teams make decisions.

• Pharmaceutical Contract Manufacturing Market Report 2026-2036
• Pharmaceutical Packaging Market Report 2026-2036
• Vaccine Contract Manufacturing Market Report 2026-2036
• mRNA Cancer Vaccine Market Report 2026-2036
• Anti-obesity Drugs Market Report 2026-2036
• Longevity Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com